Gboxin is primarily researched for its potential in targeting cancer cells, particularly in glioblastoma, a highly aggressive brain tumor. It works by inhibiting mitochondrial function in cancer cells, disrupting their energy production and leading to cell death. This selective action on cancer cells makes it a promising candidate for developing targeted cancer therapies. Research is ongoing to explore its efficacy, safety, and potential use in combination with other treatments to enhance its anticancer effects.